Joel A. Cummings

651 total citations
14 papers, 538 citations indexed

About

Joel A. Cummings is a scholar working on Physiology, Molecular Biology and Cell Biology. According to data from OpenAlex, Joel A. Cummings has authored 14 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 9 papers in Molecular Biology and 5 papers in Cell Biology. Recurrent topics in Joel A. Cummings's work include Alzheimer's disease research and treatments (10 papers), Proteoglycans and glycosaminoglycans research (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Joel A. Cummings is often cited by papers focused on Alzheimer's disease research and treatments (10 papers), Proteoglycans and glycosaminoglycans research (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Joel A. Cummings collaborates with scholars based in United States, New Zealand and Canada. Joel A. Cummings's co-authors include Alan D. Snow, Gerardo M. Castillo, Catherine Ngo, Thomas N. Wight, Martin E. Judge, Wen Yang, Malcolm J. Sheardown, John‐Bjarne Hansen, Rudolph E. Tanzi and Judy Cam and has published in prestigious journals such as Diabetes, Scientific Reports and Journal of Neurochemistry.

In The Last Decade

Joel A. Cummings

14 papers receiving 526 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel A. Cummings United States 9 300 266 194 60 58 14 538
Alexandre Fifre France 11 311 1.0× 384 1.4× 129 0.7× 83 1.4× 72 1.2× 14 754
Saori Hata Japan 13 295 1.0× 315 1.2× 128 0.7× 37 0.6× 89 1.5× 40 663
Dun-Sheng Yang Canada 6 257 0.9× 478 1.8× 199 1.0× 87 1.4× 121 2.1× 6 715
Ruth A. Valero Spain 9 454 1.5× 167 0.6× 102 0.5× 28 0.5× 68 1.2× 9 744
Maria B. Bagh United States 13 334 1.1× 242 0.9× 160 0.8× 49 0.8× 22 0.4× 20 644
Kenneth Hughes United Kingdom 7 474 1.6× 383 1.4× 156 0.8× 67 1.1× 101 1.7× 13 780
Anthony Carlo United States 11 288 1.0× 163 0.6× 75 0.4× 38 0.6× 37 0.6× 16 606
Ricardo J.S. Viana Portugal 9 321 1.1× 251 0.9× 159 0.8× 57 0.9× 52 0.9× 10 760
Elvira Lopez‐Perez France 9 433 1.4× 296 1.1× 127 0.7× 123 2.0× 78 1.3× 12 641
Jody K. Lancia United States 11 281 0.9× 280 1.1× 62 0.3× 56 0.9× 96 1.7× 14 613

Countries citing papers authored by Joel A. Cummings

Since Specialization
Citations

This map shows the geographic impact of Joel A. Cummings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel A. Cummings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel A. Cummings more than expected).

Fields of papers citing papers by Joel A. Cummings

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel A. Cummings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel A. Cummings. The network helps show where Joel A. Cummings may publish in the future.

Co-authorship network of co-authors of Joel A. Cummings

This figure shows the co-authorship network connecting the top 25 collaborators of Joel A. Cummings. A scholar is included among the top collaborators of Joel A. Cummings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel A. Cummings. Joel A. Cummings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Snow, Alan D., et al.. (2021). The Unifying Hypothesis of Alzheimer’s Disease: Heparan Sulfate Proteoglycans/Glycosaminoglycans Are Key as First Hypothesized Over 30 Years Ago. Frontiers in Aging Neuroscience. 13. 710683–710683. 54 indexed citations
2.
3.
Snow, Alan D., Gerardo M. Castillo, Beth P. Nguyen, et al.. (2019). The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. Scientific Reports. 9(1). 561–561. 55 indexed citations
4.
Hu, Qubai, et al.. (2011). P2‐529: Identification of Exebryl‐1® and other novel small molecules as tau protein aggregation inhibitors. Alzheimer s & Dementia. 7(4S_Part_14). 5 indexed citations
5.
Snow, Alan D., Joel A. Cummings, Qubai Hu, et al.. (2009). P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease. Alzheimer s & Dementia. 5(4S_Part_14). 15 indexed citations
6.
7.
8.
Cummings, Joel A., et al.. (2000). Disruption of pre-deposited Alzheimer's aβ 1–42 fibrils by PTI-00703 (cat's claw derivative) in a rodent model of Aβ fibrillogenesis. Neurobiology of Aging. 21. 153–153. 1 indexed citations
9.
Cummings, Joel A.. (2000). BOOK REVIEW. Cell Biology International. 24(1). 60–60. 1 indexed citations
10.
Castillo, Gerardo M., Joel A. Cummings, Wen Yang, et al.. (1998). Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation.. Diabetes. 47(4). 612–620. 115 indexed citations
11.
Castillo, Gerardo M., Catherine Ngo, Joel A. Cummings, Thomas N. Wight, & Alan D. Snow. (1997). Perlecan Binds to the β‐Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability. Journal of Neurochemistry. 69(6). 2452–2465. 218 indexed citations
12.
13.
14.
Cummings, Joel A., et al.. (1995). Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.. PubMed. 10(7). 515–27. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexandre Fifre Breakdown of academic impact, for papers by Saori Hata Breakdown of academic impact, for papers by Dun-Sheng Yang Breakdown of academic impact, for papers by Ruth A. Valero Breakdown of academic impact, for papers by Maria B. Bagh Breakdown of academic impact, for papers by Kenneth Hughes Breakdown of academic impact, for papers by Anthony Carlo Breakdown of academic impact, for papers by Ricardo J.S. Viana Breakdown of academic impact, for papers by Elvira Lopez‐Perez Breakdown of academic impact, for papers by Jody K. Lancia
Rankless by CCL
2026